Detailed Agenda
|
Time
|
Title/Description
|
Speakers/Location
|
|
Monday, June 22, 2009
|
|
17:30-19:30
|
Welcome Reception – Hosted by BayHelix
Meet other attendees and members of the prestigious BayHelix group at this informal reception. BayHelix is an organization of 170 business leaders of Chinese heritage that foster the growth of the life sciences and healthcare industry in the Pacific Rim and beyond.
|
Howard Johnson Hotel – Zhangjiang Hi-Tech Park
|
|
Day 1 – Tuesday, June 23, 2009
|
|
8:00-9:00
|
Breakfast/Networking
|
Food and beverage area
|
|
9:00-9:15
|
Opening Remarks
|
Greg Scott - President & Founder, ChinaBio LLC
Carola Schropp, MBA - Founder and Presidnet, EBD Group
|
|
9:15-10:30
|
Keynote Panel: Partnering in China – the New Frontier
China has become a global hotbed of technology development for big pharma. All of the large multinational companies now have R&D centers in China, most based in Shanghai. As its domestic industry rapidly evolves, China offers a growing number of collaboration and partnering opportunities with emerging companies, universities and institutes. This keynote panel examines questions relevant to all pharma and biotech companies looking for partnering opportunities in China:
- Why is China attractive as a location for both R&D and partnering?
- What types of opportunities are big pharma seeking in China?
- How is partnering different in China than in the West?
- What hurdles do multinational companies face when looking to partner in China?
- How can early stage companies and researchers in China attract the attention of big pharma?
|
Moderator: Greg Scott - President & Founder, ChinaBio LLC
Panelists:
Liam Condon, MBA - Managing Director, Bayer Healthcare China
Samantha Du, PhD – CEO, Hutchinson MediPharma
Alex Fowkes, JD - Executive Director, Head of R&D Business Development, Asia, Pfizer Global Research and development
Mervyn J. Turner, PhD - Chief Strategy Officer, Merck & Co., Inc.
Gerald Chan, DSc - Co-Founder, Morningside
|
|
10:30-11:00
|
Break/Networking
|
Food and beverage area
|
|
11:00-12:00
|
Panel 1: Capital Outlook for China Biopharma
The financial crisis has changed the international biopharmaceutical landscape dramatically. In China, a unique set of circumstances, including government funding, big pharma interest, and continued VC funding, make the current climate there more positive than elsewhere in the world. Learn from financial experts focused on China’s life science industry, what opportunities and challenges the future may hold.
|
Moderator: Helen Chen - Partner and Head of China Life Sciences, L.E.K. Consulting
Panelists:
Carl Firth, PhD, MBA – Director, Head of Asia Healthcare, Bank of AmericaMerrill Lynch
Yvonne Gunsch-Wegmann, MD, MBA - Vice President, Head of Issuer and Investor Relations, SIX Swiss Exchange
Bo Wen, MBA - Managing Director, The Balloch Group
Chika Yoshinaga Yao, MD - Vice President of Asia, Sofinnova Partners
|
|
12:00-13:30
|
Buffet Lunch/Networking – Sponsored by Hutchison MediPharma
|
Banquet Hall across from the Auditorium
|
|
13:30-14:30
|
Workshop 1: Cross-border Licensing of Early-Stage Technologies – Legal and Business Challenges
The world's capital markets crisis has intensified the importance of licensing and collaborations as a means for companies to finance their growth and progress. Foreign pharmaceutical and biotech companies seeking profitable licensing and collaboration opportunities are looking to China as a vital market for R&D, manufacturing, and commercialization. How can Chinese companies prepare themselves for licensing and collaboration transactions with foreign entities? What preparations should be made by foreign companies to avoid pitfalls in these agreements? This presentation will examine and address:
- The Basic Building Blocks of Agreements, From Simple to Complex
- Advance Preparation Necessary to Properly Prepare for Negotiating an Agreement
- The Terms of IP Licenses in Detail and Review Negotiating Strategies
- Ten Rules to Complete Your Deals Successfully
|
Chair: Brian Cunningham, JD - Senior Counsel and Co-Chair of Life Sciences Group, Morrison & Foerster
|
|
14:30-15:30
|
Workshop 2: The Anatomy of Partnering with Big Pharma – an A-Z Approach
A partnering agreement with a pharmaceutical company may be one of the most complex transactions a biotech company will enter into as part of its business operations. Understanding the negotiation process, the structure of the agreement and the significance and potential pitfalls of certain critical terms can play a big role in forming a successful collaboration. This panel will discuss the steps involved in entering into a partnering deal, from preparation to negotiation to execution and implementation.
|
Introduction: RoseAnn Rotandaro, JD - President and Co-Founder, Virtual Law Partners LLP
Chair: Ellen Leznik, MBA, JD - Founding Partner, Virtual Law Partners LLP
Panelists:
John Rigsbee, PhD, JD – Partner, Virtual Law Partners LLP
Geoff Willard, JD – Partner, Virtual Law Partners LLP
Tao Xiong, JD - Partner, Broad & Bright
Changchun Yuan, JD - Partner, Broad & Bright
|
|
15:30-16:00
|
Break/Networks
|
Food and beverage area
|
|
16:00-17:00
|
Workshop 3: How to Structure Your Company Operations in China
A right corporate structure is often essential for doing business in China. Important and practical considerations in structuring a life sciences company will be discussed. Several examples will be provided to demonstrate how effective corporate structures enable successful business transactions and how incorrect corporate structures can prevent business partners from achieving their goals. Technology transfer, collaboration, partnering and service deal structures and their relationship with corporate structure and intellectual property strategy will also be discussed.
|
Chair: Wei Zhou, PhD, JD – Partner, Wilson Sonsini Goodrich & Rosati
|
|
17:00-18:00
|
Shuttle Bus to Banquet
|
Meet on the 1st floor at the entrance
|
|
18:00-20:00
|
Gala Banquet – Sea Palace Floating Restaurant
Located in the fastest growing area of Shanghai and China’s financial center, Pudong, on the famous Huangpu River. See the Bund, the Pearl Tower, Jinmao Tower and the new Shanghai World Financial Center, the 3rd tallest building in the world while you enjoy classic Chinese dishes.
|
Sponsored by: Medicilon/MPI
|
|
Day 2 – Wednesday, June 24, 2009
|
|
8:00-9:00
|
Breakfast/Networking
|
Food and beverage area
|
|
9:00-10:00
|
Panel 2: China’s Outsourcing Revolution
Dwindling pipelines and shrinking revenue are problems most pharmaceutical companies are facing today. To make R&D more efficient, many of them are building virtual development groups, especially in China where costs are much lower. As a result, the CRO/CMO industry is booming, and in fact, two of the largest CRO facilities in the world are currently being built in China. This panel will examine the impact of the outsourcing revolution in China and how it is creating opportunities for increased productivity and collaborative development projects as well as lowered costs.
|
Moderator: Wendy R. Jory, PhD, MBA - Services Segment Leader, Discovery Services, Life Technologies
Panelists:
Darren Ji, MD, PhD, MBA – CEO, PharmaLegacy Laboratories (Shanghai) Co., Ltd.
R. Stephen Porter, PharmD - CSO, Medicilon/MPI Preclinical Research
Richard Wang, PhD, MBA - Director, Strategic Alliance and Collaboration, AstraZeneca
Dan Zhang, MD, MPH - Chairman and CEO, Fountain Medical Development Ltd.
|
|
10:00-11:00
|
Panel 3: Life Science Clusters in China – Where, What and How
The China government has created a strong financial stimulus to build a solid domestic biotech/biopharma industry. This has resulted in the launch of several major life science clusters throughout China. Officials and executives from the top life science parks and agencies in China present the advantages each region offers and specific incentive programs, as well as a “where to” and “how to” approach to establishing a presence in China.
|
Moderator: Don Qiu, PhD, MBA - General Manager, ChinaBio LLC
Panelists:
Stephen Lam, PhD, MBA - Senior Manager, Life Science/Biotech, Marketing and Admission, HKSTP
Yuwen Liu, MBA - General Manager, Suzhou/BioBay
Xiaolin Wei, PhD, MD, MPH - Vice General Manager, Shanghai Z.J. Biotech & Pharmaceutical Base Development Co., Ltd.
|
|
11:00-12:00
|
Panel 4: From Research to Commercialization – Starting at Square One
Commercializing early stage technology is a challenge anywhere in the world. Starting with essentially a clean sheet, China has the opportunity to do things differently. This also means that there is little experience and expertise at hand to draw from. The panel examines what is currently working in China, what is not, what lessons can be gleaned from the experience in the U.S. and Europe, and how to be successful at moving technology developed in China from the lab into the clinic.
|
Moderator: David Flores - Co-Founder, President and CEO, BioCentury Publications
Panelists:
Kevin Chen, MBA – COO, ShangPharma Corporation
Frank Grams, PhD - Executive Director, Roche Pharma Partnering, Asia
Jennifer Hu, PhD - Director of Licensing & External Research, Merck & Co., Inc., USA
Yi Zhun Zhu, MD, PhD - Dean, School of Pharmacy Fudan University
|
|
12:00-13:30
|
Buffet Lunch/Networking
|
Banquet Hall across from the Auditorium
|
|
13:30-14:30
|
Workshop 4: Cross-border M&A and Strategic Alliances in China - Opportunities & Challenges
China's rapidly growing drug market has become essential for all big pharma and biotech players. These companies are forming strategic alliances with China companies for R&D, manufacturing, commercialization as well as service. Influenced by government incentives and the rapidly growing talent pool, Chinese life sciences companies are becoming competitive on an international level. As a consequence, more cross-border M&As are occurring. The seasoned speakers will address in detail the opportunities and challenges accompanying these transactions.
|
Chair: Ruediger Herrmann, PhD – Partner, WilmerHale
Panelists:
Carl Firth, PhD, MBA – Director, Head of Asia Healthcare, Bank of AmericaMerrill Lynch
Michael Heerde, PhD - Director, Strategy and Business Development, Bayer Healthcare China
Kewen Jin, PhD -General Manager, Charles River Greater China
Victor Shi, PhD -Asia President,QIAGEN
|
|
14:30-15:30
|
Workshop 5: Building a Global Patent Portfolio and Protecting Your IP in China
This panel will discuss challenges faced by pharmaceutical companies in conducting R&D activities in China especially issues and concerns relating to patent protection, and strategies for protecting and strengthening IPRs in China and worldwide.
|
Moderator: Zoe Wang, PhD, JD – Partner, Perkins Coie LLP
Panelists:
Haiyan Chen, PhD, JD - IP Counsel, GlaxoSmithKline R&D China
Kening Li, PhD, JD - Partner, Pinsent Masons LLP
James Zhu, PhD, JD, MBA – Partner, Perkins Coie
Zhiqiang Zhao, PhD, JD - Chief IP Counsel, Rohm and Haas Company
|
|
17:00-18:00
|
Closing Reception
|
Food and beverage area
|
|
Please log in to the partneringONE™ system.
|
